ストックスクリーナーアプリを入手
1.11
0.00%
0.00
前日終値:
$1.11
開ける：
$1.14
24時間の取引高:
1.09M
Relative Volume:
0.65
時価総額：
$29.93M
収益：
$16.77M
当期純損益:
$-11.87M
株価収益率:
-2.3408
EPS:
-0.4742
ネットキャッシュフロー:
$-5.90M
1週間 パフォーマンス:
+10.45%
1か月 パフォーマンス:
+107.87%
6か月 パフォーマンス:
+170.73%
1年 パフォーマンス:
+12.12%
1日の値動き範囲:
$1.05
$1.16
1週間の範囲:
$0.82
$1.16
52週間の値動き範囲:
$0.30
$1.16
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
IPA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IPA
Immunoprecise Antibodies Ltd
|
1.11 | 29.93M | 16.77M | -11.87M | -5.90M | -0.4742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-25 | 開始されました | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd (IPA) 最新ニュース
Market Recap: ImmunoPrecise Antibodies Ltd (IPA)’s Positive Momentum, Closing at 0.95 - DWinneX
We're Keeping An Eye On ImmunoPrecise Antibodies' (NASDAQ:IPA) Cash Burn Rate - Yahoo Finance
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Sees Large Growth in Short Interest - Defense World
ImmunoPrecise stock rating reiterated at Buy by H.C. Wainwright - Investing.com India
ImmunoPrecise Antibodies (IPA) Showcases Groundbreaking AI-Desig - GuruFocus
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass - GuruFocus
Esty, America's Car-Mart, ImmunoPrecise - TradingView
ImmunoPrecise’s AI-Designed Peptides Surpass Semaglutide in Receptor Activation - TipRanks
ImmunoPrecise Antibodies Says AI-Designed GLP-1 Peptides Surpass Semaglutide In Receptor Activation - MarketScreener
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies - The Joplin Globe
Immunoprecise Antibodies discovers highly conserved epitope across all four dengue virus serotypes - BioWorld MedTech
ImmunoPrecise jumps on reported vaccine breakthrough - The Pharma Letter
ImmunoPrecise Antibodies (OTCMKTS:IPATF) Trading Up 1.8% – Here’s What Happened - Defense World
ImmunoPrecise identifies universal dengue vaccine target By Investing.com - Investing.com South Africa
ImmunoPrecise Antibodies (IPA) Makes Breakthrough in Dengue Vacc - GuruFocus
Immunoprecise Announces Ai-Driven Breakthrough In Universal Dengue Vaccine Discovery - marketscreener.com
ImmunoPrecise Unveils AI-Driven Breakthrough in Dengue Vaccine Discovery - TipRanks
ImmunoPrecise identifies universal dengue vaccine target - Investing.com
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery | IPA Stock News - GuruFocus
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery - Yahoo Finance
ImmunoPrecise Antibodies (NASDAQ:IPA) Stock Rating Upgraded by Wall Street Zen - Defense World
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Eng - GuruFocus
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts - Yahoo Finance
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference | IPA Stock News - GuruFocus
ImmunoPrecise Antibodies to Present at Maxim Group’s 2025 Virtual Tech Conference - TipRanks
AI Breakthrough: ImmunoPrecise CEO Reveals Next-Gen Biotherapeutics Strategy at Major Tech Conference - Stock Titan
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference - New Castle News
What's Going on With Apple Stock? - The Globe and Mail
ImmunoPrecise Antibodies (IPA) Showcases Breakthrough in Epitope Mapping | IPA Stock News - GuruFocus
ImmunoPrecise Antibodies’ LENSai Platform Revolutionizes Epitope Mapping - TipRanks
IPA's LENSai™ Platform Delivers X-Ray--Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed | IPA Stock News - GuruFocus
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed - Yahoo Finance
ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Shares Leap 28% Yet They're Still Not Telling The Full Story - simplywall.st
ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery - ACCESS Newswire
How ImmunoPrecise Antibodies ($IPA) Uses AI to Transform Antibody-Based Drug Discovery - Podomatic
IPAImmunoprecise Latest Stock News & Market Updates - Stock Titan
Views of Wall Street’s Leading Experts on ImmunoPrecise Antibodies Ltd - Sete News
ImmunoPrecise Antibodies (OTCMKTS:IPATF) Trading Down 7% – Should You Sell? - Defense World
What is going on with ImmunoPrecise Antibodies Ltd? Sentiment Analysis - uspostnews.com
Will ImmunoPrecise Antibodies (NASDAQ:IPA) Spend Its Cash Wisely? - simplywall.st
H.C. Wainwright sets $50 target for ImmunoPrecise stock - Investing.com Australia
H.C. Wainwright sets $50 target for ImmunoPrecise stock By Investing.com - Investing.com South Africa
ImmunoPrecise Antibodies’ (IPA) “Buy” Rating Reiterated at HC Wainwright - Defense World
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI- - GuruFocus
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods - 01net
ImmunoPrecise Antibodies Aligns with FDA’s Move to Non-Animal Testing - TipRanks
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSaitm with FDA's Shift to Non-Animal Testing Methods - Lelezard
AI Breakthrough: How IPA's LENSai Platform Leads FDA's Historic Shift from Animal Testing - Stock Titan
ImmunoPrecise Antibodies Partners with RIBOPRO to Enhance Antibody Discovery - TipRanks
Immunoprecise Antibodies Ltd (IPA) 財務データ
収益
当期純利益
現金流量
EPS
1.11%
1.70%
大文字化:
|
ボリューム (24 時間):